Table 1.
Immunophenotype of Tal1/Lmo2 and mutTAL1/Lmo2 tumors
| Animal number | Genotype | CD3 | CD25 | DN | CD4 | CD8 | DP | Phenotype | Survival (days) |
|---|---|---|---|---|---|---|---|---|---|
| 5624 | Tal1/Lmo2 | 31.6 | 55.7 | 27.9 | 0.1 | 71.2 | 0.8 | DN, CD8-SP | 102 |
| 5629 | Tal1/Lmo2 | 71.3 | 0.4 | 30.9 | 0.2 | 68.1 | 0.7 | DN, CD8lo | 91 |
| 5632 | Tal1/Lmo2 | 94.2 | 7.7 | 1.7 | 0.2 | 82.6 | 15.5 | CD8-SP | 91 |
| 5666 | Tal1/Lmo2 | 95.1 | 95.3 | 3.3 | 2.0 | 2.1 | 92.6 | DP | 98 |
| 5354 | Tal1/Lmo2 | 29.3 | 62.9 | 30.1 | 0.6 | 4.3 | 65 | DN, DP | 47 |
| 5338 | Tal1/Lmo2 | 69.5 | 70.6 | 25.8 | 0.1 | 42.8 | 31.1 | DN, CD8-SP, DP | 86 |
| 5351 | Tal1/Lmo2 | 23.7 | 97.9 | 0.3 | 0.1 | 0.5 | 99.1 | DP | 106 |
| 5313 | Tal1/Lmo2 | 96.2 | 3.3 | 0.8 | 93.4 | 1.1 | 4.7 | CD4-SP | 154 |
| 5353 | Tal1/Lmo2 | 27.5 | 4.6 | 9.7 | 80.1 | 0.4 | 9.8 | CD4-SP | 123 |
| 6540 | mutTal1/Lmo2 | 52.7 | 13.8 | 53.7 | 8.2 | 10.9 | 27.1 | DN, DP-lo | 99 |
| 5984 | mutTal1/Lmo2 | 50.0 | 95.5 | 51.0 | 1.0 | 39.5 | 8.5 | DN, CD8-SP | 101 |
Tumors were stained with antibodies to CD3, CD4, CD8 and CD25 and analyzed by flow cytometry.
The percentage of stained cells is indicated.